New Brunswick-based Johnson & Johnson has begun clinical trials for an Ebola vaccine in Sierra Leone.
The vaccine regimen is part of a new study being conducted in Sierra Leone's Kambia district, where some of the country's most recent Ebola cases have been reported.
The study, in development at subsidiary Janssen Pharmaceutical Cos., will evaluate safety and immune response within Sierra Leone's general population.
The company said Friday that the first volunteers have received the initial dose.
Johnson & Johnson said that there are separate studies being conducted in the U.S., Europe and Africa as part of the accelerated development plan to prevent Ebola outbreaks.